Overall, 8aa has the potential to be developed as a novel EGFR inhibitor to treat NSCLC patients in general, as well as those with L858R and T790M mutations that are resistant to conventional EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.